T Cell Revival Through PD-1: Clues for Cancer Immunotherapy
Emory Health SciencesCancer immunotherapy drugs that block the inhibitory PD-1 pathway have shown success in clinical trials and are now FDA-approved for melanoma, lung cancer and bladder cancer. Yet many patients' tumors do not respond to these drugs.